PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

Publisher Name :
Date: 30-Jun-2014
No. of pages: 173
Inquire Before Buying

GlobalData's report, "PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market", provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements in various markets, recent deals activity and trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as India providing in-depth analysis of these markets' regulatory framework, key domestic players and their biosimilar pipelines, and strategic outlook.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.


About the Report

GlobalData's PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market report is an essential source of information and analysis on the global biosimilars industry. Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData provides in-depth analysis of the current and future growth drivers of the biosimilars industry. The report discusses the various regulatory frameworks under which biosimilars are currently reviewed and regulated. Furthermore, it discusses the key factors shaping and driving the biosimilars business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of biosimilars.

Key Questions Answered

What are the drivers of the global biosimilars industry?

  • Who are the top players involved in the development of biosimilars in the developed markets of Europe and the US, as well as in emerging markets, including India and China?

  • What are the major barriers to entry into the biosimilars industry?

  • What specific strategies are companies utilizing to combat some of the challenges currently facing the development of the global biosimilars industry?

  • What is the current state of biosimilars regulation in the EU, US, Japan, India, China, and South Korea?


  • The report provides analysis of the key drivers and trends shaping the global biosimilars industry.

  • The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU, as well as emerging markets such as China and India. Furthermore, it identifies key domestic players in the various markets discussed and provides analysis of their strategy, manufacturing capacity, and clinical pipeline.

  • The report contains expert insights on the corporate strategies of current and prospective players in the global biosimilars industry.

  • The report contains a special case study on Teva Pharmaceutical Industries' biosimilars business, including an in-depth SWOT analysis of the company.

Reasons to buy

  • Understand the frameworks under which biosimilars are currently being reviewed and regulated across various developed and emerging markets

  • Identify the key domestic players in various biosimilar markets, including South Korea, Japan and emerging markets such as India and China

  • Understand the key drivers and trends in the global biosimilars industry

  • Analyze and track the strategies that companies are using to enter and/or strengthen their position in the rapidly evolving biosimilars industry, as well as efforts being made by innovator companies like Amgen to protect their market position

  • Use this information as an independent source for your due diligence and transaction strategy

PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

Table of Contents

1 Table of Contents 7
1.1 List of Tables 12
1.2 List of Figures 14

2 Introduction 15
2.1 Report Scope 15
2.2 Upcoming Related Reports 16
2.3 Recently Published Reports 17

3 Market Overview 18
3.1 Biologics: An Expensive Necessity 18
3.2 Historical Branded Biologic Sales and Forecast 20
3.3 A Trickling Biologics Pipeline 22
3.4 Why Biosimilars? 22
3.4.1 Rising Healthcare Expenditures 23
3.4.2 The Need to Broaden Healthcare Coverage and Drive Macroeconomic Growth 23
3.5 Biosimilars: Not an ?Easy' Venture 23
3.5.1 Complex Manufacturing Processes 24
3.5.2 Rigorous Regulatory Requirements 25
3.5.3 No Automatic Substitution 26
3.6 Clinical Trials Landscape 26

4 Biosimilar Deals Trends 31
4.1 Highlighted Deals 32
4.1.1 Baxter International and Coherus Biosciences Announce Biosimilars Collaboration 35
4.1.2 Genor BioPharma and BioCND Form mAb Partnership for International Markets 37
4.1.3 Pfenex Forms JV with Agila Biotech 38
4.1.4 Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal 39
4.1.5 Samsung Bioepis and Merck Expand Biosimilars Development Agreement 41
4.2 Additional Deals 44

5 Biosimilars Regulation 45
5.1 Biosimilars: Different Names, Common Themes 45
5.2 WHO's Guidance on SBPs 45

6 Biosimilars in the US 47
6.1 Overview 47
6.2 The US' Evolving Regulatory Framework for Biosimilars 47
6.2.1 Big Pharma's Adverse Reaction to Section 505(b)(2) 48
6.2.2 The Patient Protection and Affordable Care Act 50
6.2.3 Recent Guidances on Biosimilars by the FDA 51
6.3 Mixed Feelings among Stakeholders as US States Embrace Biosimilar Substitution 55
6.4 Key Players and Pipelines 56
6.4.1 Hospira 56
6.4.2 Actavis 60
6.4.3 Pfizer 62
6.5 Biosimilars in the US: Market Outlook 64
6.5.1 Efforts to Establish a Regulatory Framework Favors the Development of the Industry 64
6.5.2 Increasing Healthcare Expenditures Will Drive Biosimilars Substitution 65
6.5.3 Large Biotechs and Pharmas Will Aggressively Defend their US Market Share 65
6.5.4 Patent Expirations of Blockbuster Biologics Will Encourage Biosimilar Developers 66

7 Biosimilars in Europe 67
7.1 Overview 67
7.2 EU Approved Biosimilars 67
7.3 Guidelines for Biosimilars Development in the EU 70
7.3.1 Sandoz Triggered the Development of Guidelines for Biosimilars in Europe 70
7.3.2 Applicable Guidance Documents on Biosimilars in Europe 71
7.3.3 Non-Clinical Data and Clinical Studies 72
7.4 Key Players and Pipelines 73
7.4.1 Sandoz 73
7.4.2 Stada Arzneimittel 76
7.4.3 Gedeon Richter 78
7.5 Biosimilars in Europe: Market Outlook 80
7.5.1 Financial Austerity Measures Will Further Drive the Uptake of Biosimilars 80
7.5.2 Companies Will Use the EU Biosimilars Market as a Springboard into the US Market 82

8 Biosimilars in Japan 83
8.1 Overview 83
8.2 Regulatory Framework 83
8.2.1 Organizational Structure 83
8.2.2 Biosimilars Review Process 84
8.2.3 Regulatory Guidelines 85
8.3 Key Players and Pipelines 87
8.3.1 Kyowa Hakko Kirin Co. Ltd. 87
8.3.2 JCR Pharmaceuticals 90
8.4 Biosimilars in Japan: Market Outlook 92
8.4.1 Cost Containment Measures Will Drive Biosimilars Development 92
8.4.2 CMOs Will Leverage Existing Capabilities to Enter Biosimilars Space 92

9 Biosimilars in India 93
9.1 Gradual Transition from a Semi-Regulated to a Regulated Market 93
9.2 Marketed Biosimilars in India 93
9.3 Regulatory Framework for Biosimilars in India 97
9.3.1 Guidelines on Similar Biologics, 2012 101
9.4 Key Players and Pipelines 102
9.4.1 Biocon 102
9.4.2 Dr. Reddy's Laboratories 106
9.4.3 Ranbaxy Laboratories 108
9.4.4 Reliance Life Sciences 111
9.4.5 Cipla 112
9.5 India Biosimilars Market Outlook 114
9.5.1 Recent Biosimilar Guidelines Will Not Guarantee Approval by Regulators 114
9.5.2 Expertise in Generics Will Encourage Biosimilars Development 115
9.5.3 EU-India Free Trade Agreement Could Open Up Access to the European Market 115

10 Biosimilars in South Korea 117
10.1 Overview 117
10.2 Government Initiatives Aiding the Development of Biosimilars 119
10.3 Joint Ventures and Collaborations Enable Leveraging of Capabilities 120
10.4 Lack of Biologics' Market Exclusivity Decelerates Time-to-Market 121
10.5 Regulatory Framework for Biosimilars 121
10.5.1 Extrapolation of Indications 123
10.6 Key Players and Pipelines 123
10.6.1 Celltrion 124
10.6.2 Hanwha Chemical 127
10.6.3 Samsung Bioepis 129
10.6.4 LG Life Sciences 129
10.7 Biosimilars in South Korea: Market Outlook 132
10.7.1 Government's Initiatives Look Poised to Spur the Local Biosimilars Industry 132
10.7.2 Budding Pipeline Signals Boom for the Biosimilars Industry 133

11 Biosimilars in China 134
11.1 Overview 134
11.1.1 Soaring Healthcare Expenditures in China Drive Need for Cheaper Therapeutics 134
11.1.2 Biosimilars and Reimbursement 135
11.1.3 An Intellectual Property Loophole 136
11.2 Regulatory Framework for Biosimilars in China 136
11.3 Key Players and Pipelines 138
11.3.1 3SBio 138
11.3.2 Shandong Kexing Bioproducts 140
11.4 Biosimilars in China: Market Outlook 141
11.4.1 Ongoing Reform Will Boost Biosimilars Industry 141
11.4.2 Increase in Healthcare Access Bodes Well for Biosimilars in China 141
11.4.3 Collaborations between Multinationals and Domestic Companies Will Continue 142

12 Case Study: Teva Pharmaceutical Industries 143
12.1 Business Overview 143
12.2 Biosimilars at Teva 143
12.3 Product Portfolio/Pipeline 144
12.4 Company SWOT Analysis 145
12.4.1 Strengths 145
12.4.2 Weaknesses 147
12.4.3 Opportunities 147
12.4.4 Threats 149

13 Strategic Outlook 151
13.1 Patent Expiries Will Continually Fuel Biosimilars Development 151
13.2 Flurry of Regulatory and Legislative Activities Bodes Well for Biosimilars 151
13.3 Extensive Capabilities Needed Will Serve as a Barrier to Entry in the Near to Mid-term 152
13.4 EU-India FTA Will Significantly Benefit European and Indian Biosimilars Companies 153
13.5 Cost-containment Measures Are Expected to Drive Biosimilars Substitution 154

14 Appendix 156
14.1 Bibliography 156
14.2 Abbreviations 165
14.3 Research Methodology 168
14.3.1 Coverage 168
14.3.2 Secondary Research 169
14.4 About the Author 170
14.4.1 Adam Dion, Industry Analyst 170
14.5 Director of Healthcare Industry Dynamics 170
14.6 Global Head of Healthcare 171
14.7 About the Industry Dynamics Team 171
14.8 About GlobalData 172
14.9 Disclosure Information 172
14.10 Disclaimer 172

List of Tables

Table 1: Major Biologic Products 19
Table 2: Ongoing Biosimilar Clinical Trials 27
Table 3: Overview of Biosimilars Deals Analyzed in This Report 33
Table 4: Baxter International and Coherus Biosciences Biosimilars Collaboration 36
Table 5: Genor BioPharma and BioCND Licensing Deal 37
Table 6: Pfenex's JV with Agila Biotech 38
Table 7: Viropro and Oncobiologics' Biosimilars Deal 40
Table 8: Samsung Bioepis and Merck Sign Biosimilars Development Agreement 42
Table 9: Biosimilar Evaluation Requirements - WHO, South Korea, EU, and Japan 46
Table 10: Hospira: Marketed Biosimilars 58
Table 11: Hospira: Biosimilars Developmental Pipeline 59
Table 12: Actavis' Biosimilars Pipeline 62
Table 13: Pfizer's Biosimilars Pipeline 64
Table 14: Authorized Biosimilars in the EU 69
Table 15: Sandoz: Marketed Biosimilars 74
Table 16: Sandoz: Pipeline of Developmental Biosimilars 75
Table 17: Stada Arzneimittel's Current Biosimilars Pipeline 78
Table 18: Gedeon Richter's Current Biosimilars Pipeline 80
Table 19: Kyowa Hakko Kirin's Late-stage Biologics Pipeline 89
Table 20: JCR Pharmaceuticals' Product Pipeline 91
Table 21: Currently Marketed Biosimilars in India 95
Table 22: Guidelines Applicable to the Research, Development and Marketing of Biosimilars in India 102
Table 23: Biocon: Marketed Biologics 105
Table 24: Biocon: Current Developmental Biologics Pipeline 106
Table 25: Dr. Reddy's: Marketed Biosimilars 108
Table 26: Ranbaxy's Current Biosimilars Pipeline 110
Table 27: Reliance Life Sciences: Marketed Biosimilars 112
Table 28: Reliance Life Sciences: Pipeline Biosimilars 112
Table 29: Cipla Combined Annual Manufacturing Capacities 114
Table 30: Some Biosimilars in Development by South Korean Drug Companies 118
Table 31: Deals in the South Korean Biosimilars Industry 120
Table 32: Celltrion Product Pipeline 125
Table 33: Hanwha Chemical's Current Product Pipeline 128
Table 34: LG Life Sciences' Current Product Pipeline 132
Table 35: 3SBio's Clinical Pipeline 140
Table 36: Teva Pharmaceutical Industries: Marketed and Developmental Biosimilars 145

List of Figures

Figure 1: Historical Sales of Branded Biologics, 2008-2013 and Forecast to 2019 21
Figure 2: New Biologics* Approvals by the FDA, 2006-2013 22
Figure 3: Groups of Companies Involved in Biosimilars Development 25
Figure 4: Trend in Deals in the Biosimilars Industry, 2007-2013 32
Figure 5: FDA-Recommended Stepwise Approach for Biosimilars' Development in the US 52
Figure 6: Current Guidelines on Biosimilars Regulation in the EU 71
Figure 7: Novartis' Capabilities being Leveraged by Sandoz 76
Figure 8: Public Debt and Budget Deficit-to-GDP Ratios in the Eurozone, 2013 81
Figure 9: PMDA's Current Organizational Chart 84
Figure 10: Review Process for Biosimilars in Japan 85
Figure 11: Indian Regulatory Pathway for Indigenously Manufactured Biologics 99
Figure 12: Indian Regulatory Pathway for Imported Biologics 100
Figure 13: South Korean's Three-tiered Regulatory System for Biosimilars 122
Figure 14: Celltrion Product Pipeline by Therapeutic Area 126
Figure 15: LG Life Sciences' R&D Investment, 2009-2013 (Estimated) 131
Figure 16: Total and Government Healthcare Expenditures* in China, 2001-2011 135
Figure 17: Application and Approval Procedure for Pharmaceuticals in China 137
Figure 18: Teva's Global Biosimilars Operation: A Recipe for Success 144
Figure 19: Teva Generics Sales in US vs. Rest-of-World (ROW), 2009-2012 149
Figure 20: Teva Pharmaceuticals: SWOT Analysis 150
Figure 21: Capabilities Needed for Biosimilars Development 153
Figure 22: US Healthcare Expenditure and GDP, 2001-2013 155

  • Biosimilars - The Future Transformation of Product Exclusivity in the Biotechnology Arena
    Published: 15-Jun-2009        Price: US 3900 Onwards        Pages: 53
    Biosimilars - The Future Transformation of Product Exclusivity in the Biotechnology Arena Summary The nature of biotechnology has, up until recently, prevented the threat of generic intrusion on product sales. Biologics are difficult to replicate compared to small molecules and even slight differences in manufacturing processes could lead to significant clinical differences. The US government is poised to address the need for a process by which "similar......
  • The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market
    Published: 15-May-2011        Price: US 3900 Onwards        Pages: 58
    The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market Summary Biosimilars are attracting significant attention at present as companies from all sectors of the biopharmaceutical market are investigating the opportunities they present. Opinion is split as to the true potential of this market with some predicting it will grow to the multi-billion dollar level within five years, while other......
  • Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
    Published: 17-Oct-2011        Price: US 1200 Onwards        Pages: 152
    With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. IMARC Group, one of the world's leading research and advisory firms, in its new report "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" finds that biosimilars in the US will soon represent ......
  • Biosimilar Market Analysis: India, China and Republic of Korea
    Published: 01-Jan-2012        Price: US 3500 Onwards        Pages: 337
    GBI Research’s Slidepack, Biosimilar Market Analysis: India, China and Republic of Korea analyzes the competitive and product landscape for Biosimilars in India, China and Republic of Korea. Biosimilars represent one of the key breakthroughs in the pharmaceutical industry and are being used in indications varying from chemotherapy to hepatitis C and Multiple Sclerosis (MS). Biosimilar product types include Recombinant Erythropoietin, Recombinant Granulocyte Colony Stimulating Factor (G-CSF), Int......
  • Global Biosimilars: A return to optimism?
    Published: 23-Jan-2012        Price: US 2265 Onwards        Pages: 200
    Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for market entry. Examining the market for companies The need for a settled market environment is essential if the growing numbers of biologic products losing patent protection in the next 5-10 years is to be exploited. However, progress is painfully slow and critical issues driving the market dyn......
  • Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
    Published: 25-Jun-2012        Price: US 3500 Onwards        Pages: 88
    GBI Research, the leading business intelligence provider, has released its latest report, "Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production" that provides key data, information and analysis of the major trends and issues that affect the emerging biosimilars market. The report provides a comprehensive insight into the biosimilars market, with regional market forecasts for ......
  • Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth
    Published: 10-Jul-2012        Price: US 3500 Onwards        Pages: 141
    Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth Summary GBI Research, the leading business intelligence provider, has released its latest report, “Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth” that provides key data, information and analysis of the major trends and issues affecting the biosimilar market in developed cou......
  • Global Biosimilar Market 2010-2014
    Published: 02-Oct-2012        Price: US 1500 Onwards        Pages: 29
    TechNavio's analysts forecast the Global Biosimilar market to grow at a CAGR of 52.2 percent over the period 2010-2014. One of the key factors contributing to this market growth is the rise in patent expirations of branded biopharmaceuticals. The Global Biosimilar market has also been witnessing the trend of outsourcing of biosimilar manufacturing to Asian countries. However, the risk of drug development failure could pose a challenge to the growth of this market.......
  • Therapeutic Class Report Overview - Japan Biosimilars
    Published: 28-Jan-2013        Price: US 1000 Onwards        Pages: 32
    Available at 30% discount till 31st January 2016 ¥200b worth of biologic products is going off patent by 2015 and this value exceeds ~ ¥500b if we include products that will see their patent expiries by 2021 in Japan.  There are a number of reasons to believe that follow-on-biologics or biosimilars will......
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs